At 5.3% CAGR, Middle East & Africa Lateral Flow Assay Market is Projected to be Worth US$ 722.68 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa lateral flow assay market was valued at US$ 477.13 million in 2022 and is expected to reach US$ 722.68 million by 2030, registering a CAGR of 5.3% from 2022 to 2030. Increasing use of home-based assay kits and evolving applications of lateral flow assays are among the critical factors attributed to drive the Middle East & Africa lateral flow assay market growth.

Lateral flow assays (LFA) are paper-based tests designed for the detection of analytes (condition-specific biomolecules) in complex mixtures (biological samples), wherein samples are placed in a designated spot in a test device. These tests provide results within 5-30 minutes. Lateral flow assay kits exhibit stability over various environmental conditions and prolonged shelf life. Home tests based on later flow assays permit users to test self-collected samples and get results without the assistance of a trained medical professional. These tests are generally sold over the counter. A pregnancy test kit is one of the most familiar examples of home-based lateral flow assays. Further, these assays are designed for the diagnosis of infectious diseases, cardiovascular diseases, and stigmatized diseases such as HIV. Therefore, the rising prevalence of these diseases and the increasing adoption of lateral flow assay testing in home healthcare drive the lateral flow assay market growth. During the COVID-19 pandemic, many companies introduced at-home lateral flow assays for the diagnosis of SARS-CoV-2 infection due to people's reluctance to visit hospitals or diagnostic labs for testing.

•    In October 2020, Siemens Healthineers launched the CLINITEST Rapid COVID-19 Antigen Self-Test that helps detect the infection in 15 minutes so that the infected individuals can be isolated sooner to avoid the disease spread.
  
  
•    In July 2020, BD Launched a portable, rapid point-of-care antigen test to detect SARS-CoV-2 infection in 15 minutes.
  
  
•    In September 2020, Roche launched a SARS-CoV-2 Rapid Antigen Test for markets accepting the CE Mark.
  
  On the contrary, inconsistent assay results due to procedural limitations hamper the growth of Middle East & Africa lateral flow assay market.
  
  Based on product type, the Middle East & Africa lateral flow assay market is bifurcated into kits & reagents and lateral flow readers. The kits & reagents segment held 66.5% market share in 2022, amassing US$ 317.16 million. It is projected to garner US$ 495.40 million by 2030 to register 5.7% CAGR during 2022-2030.
  
  In terms of technique, the Middle East & Africa lateral flow assay market is segmented into sandwich assay, competitive assays, and multiplex detection assay. The sandwich assay segment held 36.8% share of Middle East & Africa lateral flow assay market in 2022, amassing US$ 175.80 million. It is anticipated to garner US$ 265.08 million by 2030 to expand at 5.3% CAGR during 2022-2030.
  
  By test type, the Middle East & Africa lateral flow assay market is divided into lateral flow immunoassay and nucleic acid lateral flow assay. The lateral flow immunoassay segment held 62.1% share of Middle East & Africa lateral flow assay market in 2022, amassing US$ 296.21 million. It is projected to garner US$ 469.20 million by 2030 to expand at 5.9% CAGR from 2022 to 2030.
  
  Based on application, the Middle East & Africa lateral flow assay market is categorized into clinical testing, veterinary diagnostics, food safety & environment testing, and drug development & quality testing. The clinical testing segment held 74.9% share of Middle East & Africa lateral flow assay market in 2022, amassing US$ 357.47 million. It is predicted to garner US$ 542.35 million by 2030 to expand at 5.3% CAGR between 2022 and 2030.
  
  By end user, the Middle East & Africa lateral flow assay market is segmented into hospitals and clinics, diagnostics laboratories, homecare, veterinary clinics, pharmaceutical & biotechnology companies, and others. The hospitals and clinics segment held 44.3% share of Middle East & Africa lateral flow assay market in 2022, amassing US$ 211.34 million. It is estimated to garner US$ 326.73 million by 2030 to expand at 5.6% CAGR during 2022-2030.
  
  Based on country, the Middle East & Africa lateral flow assay market is categorized into Saudi Arabia, South Africa, the UAE, Kuwait, Oman, Qatar, Egypt, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 23.9% share of Middle East & Africa lateral flow assay market in 2022. It was assessed at US$ 114.03 million in 2022 and is likely to hit US$ 187.23 million by 2030, registering a CAGR of 6.4% during 2022-2030.
  
  Key players operating in the Middle East & Africa lateral flow assay market are F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Co, PerkinElmer Inc, Hologic Inc, QIAGEN NV, bioMerieux SA, QuidelOrtho Corp, Abbott Laboratories, Merck KGaA, Bio-Rad Laboratories Inc, and Thermo Fisher Scientific Inc, among others.
  
  
•    In May 2022, Bio-Rad Laboratories launched the CFX Duet Real-Time PCR system to support researchers in developing singleplex and duplex quantitative PCR assays. The system offers the robust thermal performance and proprietary, accurate optical shuttle system of the company's CFX Opus system.
  
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com